Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharma, a company specialising in the production of medical cannabis, has seen an increase of 50 per cent in orders. During the first month of operations purchase orders totalled $300,000
  • A trial of the companies CogniCann medicine is expected to be completed a year early due to high levels of interest. The trial will look at the effects the medicine has on participants over 65 years with alzheimers or dementia

MGC Pharma, a bio-pharma company who specialise in the medical cannabis industry, have seen a 50 per cent increase in orders to medical cannabis wholesaler and company, Health House International and Cannvalate.

During the company’s first month of operations roughly $300,000 was raised through purchase orders.

The company said it is dedicated to “creating and supplying superb cannabinoid based pharmaceutical products” with a focus on making phytomedicines readily available for pharmacies and patients.

A clinical trial testing MGC Pharma’s CogniCann medicine is expected to be completed one year ahead of schedule, due to a much larger than expected expression of interest.

The trial in conjunction with Notre Dame University, WA, will look at the effects the phytocannabinoids based medicine has on participants over 65 years with alzheimers and dementia.

A number of pre and post treatment surveys and focus groups will be organised with family members and carers of the participants to gage their perception on how well the treatment has worked.

The trial will go over 18 weeks and is expected to be completed by the second quarter of 2020.

MXC by the numbers
More From The Market Herald
Titomic (ASX:TTT) - Executive Director & Chief Technology Officer, Jeff Lang (centre)

" Titomic (ASX:TTT) eyes $9m to accelerate commercialisation activities

3D printing company Titomic (TTT) has secured firm commitments to undertake a $9 million share placement.
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" Ocean Grown Abalone (ASX:OGA) to rebrand as Rare Foods Australia

Ocean Grown Abalone (OGA) says it plans to introduce Rare Foods Australia as the masterbrand for its products.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility